ImmunityBioNASDAQ: IBRX

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockholders of record at the close of business on April 17, 2024 are entitled to vote at and participate in the Annual Meeting. Richard Adcock, the Company's Chief Executive Off.

ImmunityBio, Inc. (NASDAQ: IBRX) has released three podcasts with UroToday discussing the FDA approval of ANKTIVA® (N-803) in combination with BCG for NMIBC CIS and advancements in bladder cancer research. Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific Officer at ImmunityBio, talked about the breakthrough.

ImmunityBio (NASDAQ: IBRX) stock has surged dramatically as investors celebrate the recent approval of Anktiva, its cancer treatment. The stock has climbed for two consecutive days and is currently at its highest point since September 2021.

Depending on who you ask,  a recession  is either right around the corner, or the stock market is ready to rattle off a seismic bull run.

Pre-PDUFA positioning is a good opportunity to buy ImmunityBio stock at a low price. Multiple catalysts could drive the stock price higher over the next 24 months. ImmunityBio has the potential to become a big pharma company rather than being sold.

ImmunityBio, Inc. (IBRX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IBRX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

ImmunityBio, Inc.'s drug Anktiva received a Complete Response Letter, or CRL, from the FDA, delaying its approval for the treatment of NMIBC. The CRL was related to deficiencies in the FDA's inspection of the company's third-party contract manufacturing organizations. ImmunityBio's financial situation, including a large debt owed to its founder, raises concerns about its ability to succeed and prioritize shareholder interests.

The clinical-stage biotech's lead therapy is in trials to treat bladder cancer. The sale of company stock helped raise $470 million.

After I spent many years following Wall Street, there are a few characteristics about the “big money”  that stand out for me. One of these traits is that many if not most large investors are very reluctant to buy stocks that have a 60%-80% chance of climbing a great deal in the long term but a 10%-15% chance of plunging in the short-to-medium term.